Addressing the complex comorbidities associated with MTOR related developmental encephalopathies - COMET

HORIZON 2020 Comorbidities call



6.000.000 E.

Partners participating to the consortium

TITLE: EFFICACY AND SAFETY OF **QU**INIDINE IN CHILDREN WITH **E**PILEPTIC **E**NCEPHALOPATHY CAUSED BY GAIN-OF-FUNCTION VARIANTS IN THE **K**CNT1 POTASSIUM CHANNEL GENE

6.000.000 E.

Coordinator: Taglialatela; Co-coordinators: Perucca - Guerrini

OVERALL SCHEME OF THE QUEEK STUDY (Figure 2)



Besta – Milan
Meyer – Florence
Bambino Gesù – Rome
Necker – Paris
University Hospital - Lyon
Great Ormond Street – London
IRCCS Mondino – Pavia
EPICARE

TO COME FOR NEXT YEAR

To progress with second stage application for COMET: Deadline April 2019

Identify other calls for potential applications for rare diseases/epilepsies

Setting up an ‘Undiagnosed and rare genetic epilepsies’ working group within Epicare and a dedicated website for information exchange as a basis for reaching out larger research initiatives (liaison with WP2) and gather specific cohorts for functional studies and applications for personalised trials (C4C)